Sarepta Therapeutics Inc. Common Stock (DE) (SRPT)
Stock · NASDAQ · Health Care
$17.1as of 10/16/2026
Price chart
Active signals
SRPT Signal Track Record
How signals performed across all stocks →What SRPT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -3.3% | 47% | September 18, 2026 |
| Bollinger Band Breakout | 25 | -6.1% | 32% | September 2, 2026 |
| Bollinger Band Breakdown | 20 | +6.3% | 55% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -5.5% | 31% | August 20, 2026 |
| Any 20-session window (baseline) | -1.5% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 835
- Website
- www.sarepta.com/
Fundamentals
- 1-day range
- $17.68$18.52
- Market cap
- $1.77B
- P/E (trailing)
- —
- P/E (forward)
- 7.40
- EPS (trailing)
- $-1.82
- Dividend yield
- —
- Beta
- 0.45
- Avg. volume
- 2.99M
How Sarepta Therapeutics Inc. Common Stock (DE) Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
22 analyst ratings
Sarepta Therapeutics Inc. Common Stock (DE) Competitors
Chosen by industry and closest market cap.
- SRPTSarepta Therapeutics Inc. Common Stock (DE)$17.1▼ 3.88%Market cap $1.77BP/E —$14.68$24.68
- SNDXSyndax Pharmaceuticals Inc. Common Stock$12.9▼ 5.49%Market cap $1.76BP/E —$12.99$25.59
- GENBGenerate Biomedicines Inc. Common Stock$12.09▼ 7.43%Market cap $1.78BP/E —$11$22.67
- SEPNSepterna Inc. Common Stock$36.35▼ 2.94%Market cap $1.78BP/E —$17.55$51.1
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- PRGOPerrigo Company plc Ordinary Shares$16.63▲ 0.91%Market cap $1.74BP/E —$9.23$22.02
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics Inc. Common Stock (DE) | $1.77B | — | $17.1 | ▼ 3.88% | $14.68$24.68 |
| SNDX Syndax Pharmaceuticals Inc. Common Stock | $1.76B | — | $12.9 | ▼ 5.49% | $12.99$25.59 |
| GENB Generate Biomedicines Inc. Common Stock | $1.78B | — | $12.09 | ▼ 7.43% | $11$22.67 |
| SEPN Septerna Inc. Common Stock | $1.78B | — | $36.35 | ▼ 2.94% | $17.55$51.1 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| PRGO Perrigo Company plc Ordinary Shares | $1.74B | — | $16.63 | ▲ 0.91% | $9.23$22.02 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Sarepta Says SRP-1003 Cut Disease-Causing RNA In Cell Nucleus By Up To ~80% In Preclinical Myotonic Dystrophy Modelbenzinga · 10/14/2026
- RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17Benzinga · 10/8/2026
- Jim Cramer Explains His Hesitation Over Sarepta (SRPT) TherapeuticsYahoo · 10/7/2026
- Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’Benzinga · 10/6/2026
- HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price TargetBenzinga · 10/5/2026
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/30/2026
- JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20Benzinga · 9/30/2026
- Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' ScenarioSeekingAlpha · 9/30/2026
- Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with DuchenneYahoo · 9/30/2026
Insider Activity
Insider Actions →- Ian Michael Estepan · September 4, 2026 · Tax Withholding24.8K @ $22.22
- Louise Rodino-Klapac · September 4, 2026 · Tax Withholding21.4K @ $22.22
- Ryan Ho-Yan Wong · September 4, 2026 · Tax Withholding13.3K @ $22.22
- Cristin Rothfuss · September 4, 2026 · Tax Withholding22.0K @ $22.22
- Michael Severino · July 28, 2026 · Grant2.22M
- Michael Severino · July 28, 2026 · Grant756.1K
- Claude Nicaise · June 4, 2026 · Grant16.9K
- Deirdre P. Connelly · June 4, 2026 · Grant16.9K
- M. Kathleen Behrens · June 4, 2026 · Grant16.9K
- Michael Andrew Chambers · June 4, 2026 · Grant16.9K
- Stephen Mayo · June 4, 2026 · Grant16.9K
- Kathryn Jean Boor · June 4, 2026 · Grant16.9K
- Richard Barry · June 4, 2026 · Grant16.9K
- Hans Lennart Rudolf Wigzell · June 4, 2026 · Grant16.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 102.20M
- Total value held
- $2.15B
- Institutional holders
- 336
- Unknown14.76M
- Unknown6.61M
- Unknown6.43M
- Unknown4.59M
- Unknown4.58M
- Unknown4.14M
- Unknown3.90M
- Unknown3.82M
- Unknown2.97M
- Unknown2.60M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.